Natco Pharma climbs 10 per cent on DCGI approval to begin production of 'Black Fungus' drug

Mayank Dsij
/ Categories: Trending, Quarterly Results

Black Fungus is recently considered as epidemic by several states

The shares of Natco Pharma climbed over 10 per cent intraday on May 24, 2021, following the Drug Controller General of India (DCGI) approval to begin production of antifungal drug Amphotericin B liposomal injection, which is believed to be critical in the treatment of Mucormycosis, also called 'Black Fungus'.

India has reported more than 8,800 cases of Mucormycosis in a growing epidemic of the disease with the western states of Gujarat and Maharashtra reporting more than half of the reported cases.

Meanwhile, Natco also said the company has initiated a Phase-III clinical trial of Molnupiravir capsules in India to evaluate its efficacy in treating patients with mild COVID-19. The clinical trial is planned in 32 hospitals across the country and pre-clinical data found that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication, the drug firm noted.

At 3.15 pm on Monday, the shares Natco Pharma Limited were trading at Rs 1081.60, up by 9.16 per cent or Rs 90.80 per share, against a 0.15 per cent gain in the benchmark index. The 52-week high of the company is recorded at Rs 28.65 and the 52-week low is recorded at Rs 19.10 on BSE.
 

Rate this article:
4.5

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

Interviews28-Mar, 2024

Multibaggers28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR